Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Gene responses to RTS,S malaria vaccination in controlled human malaria study

PROVIDER: PRJNA397222 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5901930_1.fastq.gz	Fastqsanger.gz
	SRR5901930_2.fastq.gz	Fastqsanger.gz
	SRR5901940_1.fastq.gz	Fastqsanger.gz
	SRR5901940_2.fastq.gz	Fastqsanger.gz
	SRR5901950_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 550

Similar Datasets

Transcriptional responses to RTS,S induced vaccination in controlled human malaria infection studies

Project description:Identification of host responses that are induced by RTS,S vaccination in controlled malaria infection

2020-04-21 | GSE107672 | GEO

Gene expression profiling after vaccination with the RTS,S candidate malaria vaccine in a controlled human malaria infection study

Project description:RTS,S is the sole candidate vaccine shown to provide protection against infection to malaria-naive adults challenged with mosquito-borne homologous falciparum malaria and protection against infection and clinical and severe disease to volunteers in malaria-endemic Africa who were exposed to diverse Plasmodium falciparum strains. In this experiment we profiled gene expression in PBMCs after vaccination with the RTS,S candidate malaria vaccine in a controlled human malaria infection study. Subjects were vaccinated with three doses of the RTS,S candidate malaria vaccine. Blood samples for PBMC isolation and subsequent gene expression analysis were taken on day 0 (0m), day of the third vaccination (8w), 1 day post third vaccination (8w1d), 3 days post third vaccination (8w3d), the day of the infection (10w), 1 day post infection (10w1d), and 5 days post infection (10w5d). After infection the subjects were closely monitored for parasitemia. The response to the controlled infection was recorded as follows: no parasitemia (P, protected), parasitemia in the same time frame as the control group (NP, not protected), parasitemia later than the control group (DL, delayed). In addition to the experimental factors, a confounding factor was identified in the data analysis related to the use of a specific kit batch (Kit A or B).

2017-04-27 | E-MTAB-4629 | biostudies-arrayexpress

Homo sapiens

Project description:Transcriptional responses to RTS,S standard regimen (RRR) and Ad35.CS+R,R vaccination in controlled human malaria infection study

| PRJNA401870 | ENA

Gene responses to RTS,S malaria vaccination in controlled human malaria study

Project description:Identification of gene signatures that are associated with protection in RTS,S malaria vaccination study

2020-04-21 | GSE102288 | GEO

A baseline transcriptional signature associates with clinical malaria risk in RTS,S/AS01-vaccinated African children

Project description:In a phase 3 trial in African infants/children, the RTS,S/AS01 (GSK) vaccine showed moderate efficacy against clinical malaria. We aimed to identify RTS,S/AS01-induced signatures associated with clinical malaria by analyzing antigen-stimulated peripheral blood mononuclear cells sampled from a subset of trial participants at baseline and month 3 (one month post-final dose). RTS,S/AS01 vaccination was associated with downregulation of B-cell and monocyte-related blood transcriptional modules (BTMs) and upregulation of T-cell related BTMs, as well as higher month 3 (vs baseline) (CSP)-specific CD4+ T-cell responses. For some RTS,S/AS01-associated BTMs, month 3 levels correlated with anti-circumsporozoite protein (CSP) IgM and inversely with anti-CSP IgG responses. There were few RTS,S/AS01-associated BTMs whose month 3 levels correlated with malaria risk. In contrast, baseline levels of dendritic cell and monocyte RTS,S/AS01-associated BTMs correlated with malaria risk. A cross-study analysis supported generalizability of these correlations to healthy, malaria-naïve adults, suggesting inflammatory monocytes may inhibit protective RTS,S/AS01-induced responses.

2021-06-05 | GSE176156 | GEO

Homo sapiens

Project description:Systems analysis of protective immune responses to RTS,S malaria vaccination in humans

| PRJNA351258 | ENA

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Project description:This clinical trial (NCT02252640) assesses the safety and immune responses to vaccination with experimental malaria vaccine candidates RTS,S/AS01, ChAd63 ME-TRAP and MVA ME-TRAP in different combinations. All healthy volunteers were recruited in England and administered the experimental malaria vaccines. Furthermore, volunteers were infected with malaria by mosquito bites, 12 weeks after the first vaccination to assess vaccine efficacy.

2020-09-01 | GSE103874 | GEO

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

Project description:The goal of this phase 1/2a sporozoite challenge trial (NCT01883609) was to evaluate novel malaria vaccination regimens of the GSK pre-erythrocytic RTS,S/AS01B vaccine alone and concomitantly same-site administered with the viral vectors ChAd63 & MVA encoding the liver stage antigen construct ME-TRAP. Four vaccine groups were studied and received three vaccinations at a monthly interval. All subjects then underwent controlled human malaria infection (CHMI) 11 weeks after first vaccine administration.

2020-09-01 | GSE103862 | GEO

Homo sapiens

Project description:Transcriptional responses induced by controlled human malaria infection (CHMI)

| PRJNA380820 | ENA

Transcriptional responses to RTS,S standard regimen (RRR) and Ad35.CS+R,R vaccination in controlled human malaria infection study

Project description:Identification of gene signatures that are associated with RTS,S-mediated protection against controlled malaria infection

2020-04-21 | GSE103401 | GEO